Pfizer pays out on Antares drug delivery tech agreement

Pfizer's ($PFE) collaboration with Antares Pharma, using the latter's drug delivery technology to deliver an undisclosed consumer healthcare product, has hit a development milestone, delivering a $750,000 payment to Antares. The company has already received an upfront payment from the agreement, announced in December 2011, which gives Pfizer exclusive rights in North America. But we are still getting no clues as to the drug or the delivery technology, other than a hint from Paul K Wotton, president and CEO of Antares, that it "targets a significant therapeutic area." Watch and wait. Press release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

A self-injection pen prefilled with Brussels-based UCB’s Cimzia (certolizumab pegol) has been made available this week in the U.K. after a positive opinion…

Everstone, a private equity firm specializing in India and Southeast Asia, has finally decided to shell out Rs 220 crore ($33 million) to obtain a 70% stake--a…